Dosing chart / Healing & recovery

BPC-157 vs KPV

Dose, schedule, route and approval status side by side.

BPC-157KPV
StatusNot approvedNot approved
Also known asbody protection compoundalpha-MSH fragment
Typical dose250–500 mcg200–500 mcg
How oftenDailyDaily
ScheduleDaily, often split into two doses.Once daily.
Daily equivalent250–500 mcg/day200–500 mcg/day
RouteSubcutaneous or oralSubcutaneous or oral
Duration4–8 weeks reported4–8 weeks reported
NotesNearly all evidence is from animal studies, and doses are community-reported. The FDA lists it as a compounding substance that may pose safety risks; in July 2026 an FDA advisory committee voted to recommend allowing compounding, and the FDA had not acted on that as of October 2026.Anti-inflammatory tripeptide studied in cells and animals only. There is no human dosing data; doses are community-reported.

This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the BPC-157 and KPV pages.

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.